tiprankstipranks
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
US Market
BTAI
Bioxcel Therapeutics
RESEARCH TOOLSreports
Want to see BTAI full AI Analyst Report?

Bioxcel Therapeutics (BTAI) Ratios

1,939 Followers

Bioxcel Therapeutics Ratios

BTAI's free cash flow for Q4 2025 was $0.59. For the 2025 fiscal year, BTAI's free cash flow was decreased by $ and operating cash flow was $-39.75. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 0.83 0.83 1.68 2.65 6.17
Quick Ratio
 0.82 0.82 1.65 2.57 6.11
Cash Ratio
 0.53 0.53 1.34 2.39 5.89
Solvency Ratio
 -0.50 -0.50 -0.45 -1.37 -1.28
Operating Cash Flow Ratio
 -1.07 -1.07 -3.24 -5.68 -4.11
Short-Term Operating Cash Flow Coverage
 -2.31 -2.31 0.00 0.00 0.00
Net Current Asset Value
$ -95.69M$ -95.69M$ -94.05M$ -58.07M$ 73.79M
Leverage Ratios
Debt-to-Assets Ratio
 2.44 2.44 2.69 1.38 0.46
Debt-to-Equity Ratio
 -1.15 -1.15 -1.11 -1.79 1.23
Debt-to-Capital Ratio
 7.76 7.76 10.46 2.26 0.55
Long-Term Debt-to-Capital Ratio
 -7.84 -7.84 10.90 2.28 0.55
Financial Leverage Ratio
 -0.47 -0.47 -0.41 -1.30 2.68
Debt Service Coverage Ratio
 -1.44 -1.18 -2.92 -12.42 -19.14
Interest Coverage Ratio
 -3.85 -2.93 -4.44 -12.90 -19.44
Debt to Market Cap
 3.16 5.61 6.76 1.17 0.15
Interest Debt Per Share
 10.04 10.37 46.58 63.00 58.47
Net Debt to EBITDA
 -1.49 -1.64 -1.66 -0.22 0.63
Profitability Margins
Gross Profit Margin
51.25%27.73%5.43%8.70%94.67%
EBIT Margin
-8557.48%-7742.21%-1962.49%-12010.07%-42011.73%
EBITDA Margin
-8510.75%-7695.48%-1948.85%-11987.03%-41924.53%
Operating Profit Margin
-7796.57%-7742.21%-2967.56%-12447.97%-42572.00%
Pretax Profit Margin
-10887.38%-10887.38%-2630.14%-12974.86%-44201.87%
Net Profit Margin
-10887.38%-10887.38%-2630.14%-12974.86%-44201.87%
Continuous Operations Profit Margin
-10887.38%-10887.38%-2630.14%-12974.86%-44201.87%
Net Income Per EBT
100.00%100.00%100.00%100.00%100.00%
EBT Per EBIT
139.64%140.62%88.63%104.23%103.83%
Return on Assets (ROA)
-155.62%-155.62%-155.46%-242.94%-80.52%
Return on Equity (ROE)
73.15%73.22%64.02%316.86%-215.90%
Return on Capital Employed (ROCE)
555.54%551.66%-417.54%-369.94%-92.30%
Return on Invested Capital (ROIC)
-314.39%-312.20%-408.06%-367.20%-92.13%
Return on Tangible Assets
-155.62%-155.62%-155.46%-242.94%-80.52%
Earnings Yield
-454.41%-357.84%-393.15%-208.37%-27.55%
Efficiency Ratios
Receivables Turnover
 2.76 2.76 17.30 19.44 1.51
Payables Turnover
 0.02 0.03 0.13 0.09 <0.01
Inventory Turnover
 0.43 0.64 3.16 0.63 0.01
Fixed Asset Turnover
 2.78 2.78 2.64 0.94 0.18
Asset Turnover
 0.01 0.01 0.06 0.02 <0.01
Working Capital Turnover Ratio
 -0.49 0.22 0.08 0.01 <0.01
Cash Conversion Cycle
 -16.17K -10.86K -2.59K -3.36K -150.19K
Days of Sales Outstanding
 132.47 132.47 21.10 18.78 241.39
Days of Inventory Outstanding
 841.95 567.95 115.65 576.76 36.23K
Days of Payables Outstanding
 17.14K 11.56K 2.72K 3.96K 186.66K
Operating Cycle
 974.42 700.42 136.75 595.54 36.47K
Cash Flow Ratios
Operating Cash Flow Per Share
 -4.72 -4.72 -28.41 -85.14 -77.30
Free Cash Flow Per Share
 -4.72 -4.72 -28.41 -85.15 -77.38
CapEx Per Share
 0.00 0.00 0.00 0.01 0.08
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 0.00 0.00 0.00 -7.75K -973.68
Capital Expenditure Coverage Ratio
 0.00 0.00 0.00 -7.75K -973.68
Operating Cash Flow Coverage Ratio
 -0.53 -0.53 -0.70 -1.53 -1.44
Operating Cash Flow to Sales Ratio
 -89.74 -89.74 -31.79 -112.32 -360.91
Free Cash Flow Yield
-168.89%-294.97%-475.13%-180.41%-22.51%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -0.22 -0.28 -0.25 -0.48 -3.63
Price-to-Sales (P/S) Ratio
 53.98 30.42 6.69 62.27 1.60K
Price-to-Book (P/B) Ratio
 -0.16 -0.20 -0.16 -1.52 7.84
Price-to-Free Cash Flow (P/FCF) Ratio
 -0.60 -0.34 -0.21 -0.55 -4.44
Price-to-Operating Cash Flow Ratio
 -0.27 -0.34 -0.21 -0.55 -4.45
Price-to-Earnings Growth (PEG) Ratio
 >-0.01 <0.01 <0.01 -0.12 -0.08
Price-to-Fair Value
 -0.16 -0.20 -0.16 -1.52 7.84
Enterprise Value Multiple
 -2.12 -2.04 -2.00 -0.74 -3.19
Enterprise Value
 115.29M 100.71M 88.25M 122.09M 502.19M
EV to EBITDA
 -2.11 -2.04 -2.00 -0.74 -3.19
EV to Sales
 179.58 156.87 38.95 88.47 1.34K
EV to Free Cash Flow
 -2.00 -1.75 -1.23 -0.79 -3.71
EV to Operating Cash Flow
 -2.00 -1.75 -1.23 -0.79 -3.71
Tangible Book Value Per Share
 -7.82 -7.82 -36.73 -31.04 43.85
Shareholders’ Equity Per Share
 -7.82 -7.82 -36.73 -31.04 43.85
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 0.00 0.00
Revenue Per Share
 0.05 0.05 0.89 0.76 0.21
Net Income Per Share
 -5.73 -5.73 -23.51 -98.35 -94.67
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 1.27 1.41 1.34 1.08 1.05
Research & Development to Revenue
 46.56 47.12 13.43 61.11 243.30
SG&A to Revenue
 31.92 31.92 15.22 46.02 148.68
Stock-Based Compensation to Revenue
 4.31 4.31 2.72 13.49 46.23
Income Quality
 0.82 0.82 1.21 0.87 0.82
Currency in USD